公开(公告)号：PL347138A1

公开(公告)日：2002-03-25

申请号：PL34713899

申请日：1999-09-17

Applicant: BASF AG

Inventor： CALDERWOOD DAVID ,  ARNOLD LEE D ,  MAZDIYASNI HORMOZ ,  HIRST GAVIN ,  DENG BOJUAN B ,  JOHNSTON DAVID N ,  RAFFERTY PAUL ,  TOMETZKI GERALD B ,  TWIGGER HELEN L ,  MUNSCHAUER RAINER

IPC: A61K31/519 ,  A61P1/04 ,  A61P3/10 ,  A61P9/00 ,  A61P11/00 ,  A61P15/00 ,  A61P17/02 ,  A61P19/02 ,  A61P27/00 ,  A61P29/00 ,  A61P35/00 ,  A61P37/02 ,  A61P43/00 ,  C07D487/04 ,  A61K31/505

Abstract: Chemical compounds having structural formula (I) and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases whose activity is inhibited by these compounds are involved in immunologic, hyperproliferative or angiogenic processes. Thus, these compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferative is a factor. These compounds can be used to treat cancer, hyperproliferation disorders, rheumatoid arthritis, disorders of the immune system, transplant rejection, and inflammatory disorders.

公开(公告)号：ZA200102204B

公开(公告)日：2002-03-18

申请号：ZA200102204

申请日：2001-03-16

Applicant: BASF AG

Inventor： HIRST GAVIN C ,  CALDERWOOD DAVID ,  MUNSCHAUER RAINER ,  ARNOLD LEE D ,  JOHNSTON DAVID N ,  RAFFERTY PAUL

IPC: A61K20060101 ,  C07D20060101 ,  C07D ,  A61K

公开(公告)号：CZ2001959A3

公开(公告)日：2001-12-12

申请号：CZ2001959

申请日：1999-09-17

Applicant: BASF AG

Inventor： CALDERWOOD DAVID ,  ARNOLD LEE D ,  MAZDIYASNI HORMOZ ,  HIRST GAVIN ,  DENG BOJUAN B

IPC: A61K31/519 ,  A61P1/04 ,  A61P3/10 ,  A61P9/00 ,  A61P11/00 ,  A61P15/00 ,  A61P17/02 ,  A61P19/02 ,  A61P27/00 ,  A61P29/00 ,  A61P35/00 ,  A61P37/02 ,  A61P43/00 ,  C07D487/04 ,  A61K31/505 ,  A61P35/04

Abstract: Chemical compounds having structural formula (I) and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases whose activity is inhibited by these compounds are involved in immunologic, hyperproliferative or angiogenic processes. Thus, these compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferative is a factor. These compounds can be used to treat cancer, hyperproliferation disorders, rheumatoid arthritis, disorders of the immune system, transplant rejection, and inflammatory disorders.

公开(公告)号：BR9913887A

公开(公告)日：2001-10-23

申请号：BR9913887

申请日：1999-09-17

Applicant: BASF AG

Inventor： HIRST GAVIN C ,  CALDERWOOD DAVID ,  MUNSCHAUER RAINER ,  ARNOLD LEE D ,  JOHNSTON DAVID N ,  RAFFERTY PAUL

IPC: A61K31/519 ,  A61P1/04 ,  A61P3/10 ,  A61P5/14 ,  A61P9/00 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P15/00 ,  A61P17/06 ,  A61P19/02 ,  A61P21/00 ,  A61P25/00 ,  A61P27/02 ,  A61P29/00 ,  A61P31/04 ,  A61P31/12 ,  A61P31/18 ,  A61P35/00 ,  A61P37/00 ,  A61P43/00 ,  C07D487/04 ,  C07F9/6561 ,  C07F9/6584 ,  A61K31/505

Abstract: Chemical compounds having structural formula (I) and physiologically acceptable salts and metabolites thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases, whose activity is inhibited by these chemical compounds, are involved in immunologic, hyperproliferative, or angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyper proliferative disorders, rheumatoid arthritis, disorders of the immune system, transplant rejections and imflammatory disorders.

公开(公告)号：AU4057000A

公开(公告)日：2001-10-08

申请号：AU4057000

申请日：2000-03-29

Applicant: BASF AG

Inventor： HIRST GAVIN C ,  CALDERWOOD DAVID ,  MUNSCHAUER RAINER ,  ARNOLD LEE D ,  JOHNSTON DAVID N ,  RAFFERTY PAUL

IPC: C07D487/04 ,  A61K31/505 ,  A61P35/00

公开(公告)号：NO20011357A

公开(公告)日：2001-05-14

申请号：NO20011357

申请日：2001-03-16

Applicant: BASF AG

Inventor： CALDERWOOD DAVID ,  ARNOLD LEE DANIEL ,  MAZDIYASNI HORMOZ ,  HIRST GAVIN C ,  DENG BOJUAN B

IPC: A61K31/519 ,  A61P1/04 ,  A61P3/10 ,  A61P9/00 ,  A61P11/00 ,  A61P15/00 ,  A61P17/02 ,  A61P19/02 ,  A61P27/00 ,  A61P29/00 ,  A61P35/00 ,  A61P37/02 ,  A61P43/00 ,  C07D487/04 ,  A61K31/505

CPC classification number: C07D487/04

公开(公告)号：NO20011357D0

公开(公告)日：2001-03-16

申请号：NO20011357

申请日：2001-03-16

Applicant: BASF AG

Inventor： CALDERWOOD DAVID ,  ARNOLD LEE DANIEL ,  MAZDIYASNI HORMOZ ,  HIRST GAVIN C ,  DENG BOJUAN B

IPC: A61K31/519 ,  A61P1/04 ,  A61P3/10 ,  A61P9/00 ,  A61P11/00 ,  A61P15/00 ,  A61P17/02 ,  A61P19/02 ,  A61P27/00 ,  A61P29/00 ,  A61P35/00 ,  A61P37/02 ,  A61P43/00 ,  C07D487/04 ,  C07D

Abstract: Chemical compounds having structural formula (I) and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases whose activity is inhibited by these compounds are involved in immunologic, hyperproliferative or angiogenic processes. Thus, these compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferative is a factor. These compounds can be used to treat cancer, hyperproliferation disorders, rheumatoid arthritis, disorders of the immune system, transplant rejection, and inflammatory disorders.

公开(公告)号：NO20011356D0

公开(公告)日：2001-03-16

申请号：NO20011356

申请日：2001-03-16

Applicant: BASF AG

Inventor： HIRST GAVIN C ,  CALDERWOOD DAVID ,  WISHART NEIL ,  RITTER KURT ,  ARNOLD LEE DANIEL

IPC: A61K31/519 ,  A61P1/04 ,  A61P3/10 ,  A61P5/14 ,  A61P9/00 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P15/00 ,  A61P17/06 ,  A61P19/02 ,  A61P21/00 ,  A61P25/00 ,  A61P27/02 ,  A61P29/00 ,  A61P31/04 ,  A61P31/12 ,  A61P31/18 ,  A61P35/00 ,  A61P37/00 ,  A61P43/00 ,  C07D487/04 ,  C07F9/6561 ,  C07F9/6584 ,  C07D

Abstract: Chemical compounds having structural formula (I) and physiologically acceptable salts and metabolites thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases, whose activity is inhibited by these chemical compounds, are involved in immunologic, hyperproliferative, or angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyper proliferative disorders, rheumatoid arthritis, disorders of the immune system, transplant rejections and imflammatory disorders.

公开(公告)号：CA2344249A1

公开(公告)日：2000-03-30

申请号：CA2344249

申请日：1999-09-17

Applicant: BASF AG

Inventor： HIRST GAVIN C ,  CALDERWOOD DAVID ,  ARNOLD LEE D ,  MUNSCHAUER RAINER ,  RAFFERTY PAUL ,  JOHNSTON DAVID N

IPC: A61K31/519 ,  A61P1/04 ,  A61P3/10 ,  A61P5/14 ,  A61P9/00 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P15/00 ,  A61P17/06 ,  A61P19/02 ,  A61P21/00 ,  A61P25/00 ,  A61P27/02 ,  A61P29/00 ,  A61P31/04 ,  A61P31/12 ,  A61P31/18 ,  A61P35/00 ,  A61P37/00 ,  A61P43/00 ,  C07D487/04 ,  C07F9/6561 ,  C07F9/6584 ,  A61K31/505

Abstract: Chemical compounds having structural formula (I) and physiologically acceptable salts and metabolites thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases, whose activity is inhibited by these chemical compounds, are involved in immunologic, hyperproliferative, or angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyper proliferative disorders, rheumatoid arthritis, disorders of the immune system, transplant rejections and imflammatory disorders.